Cabergoline is still not proven for these pituitary tumors
Original title: Cabergoline for non-functioning pituitary adenomas: an update on an old clinical controversy.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This looks across many earlier studies rather than running a new one.
This is a review of past studies, not a new result.
The short version
Experts reviewed the studies and found cabergoline is still not proven for these tumors.
What was studied. Doctors reviewed past studies of a drug called cabergoline for pituitary tumors that do not make extra hormones. They searched medical journals through 27 September 2026 and wrote up what the studies showed.
What they found. One review of earlier studies found the tumor shrank by at least 20% in 19% of people, and growth was stopped in 50%. A 2024 study of people who had not had surgery found shrinkage in 20%, no change in 48%, and growth in 32%. Other studies found no clear scan benefit over simply watching the tumor, and untreated tumors sometimes shrink or stay the same on their own.
What this means, and what it doesn't
What it could mean: Cabergoline is not standard care for this kind of tumor. Doctors will usually suggest watching the tumor, surgery, or radiation. Some doctors still try this drug off label. You can ask your care team if it fits your case.
What it doesn't mean: This is not a new treatment and it is not a cure. It is a look back at older studies, not a new trial. The scans sometimes changed, but that does not prove people felt or did better. Nothing here changes the care you can get today. The authors say better studies are still needed.
Source: PubMed, October 16, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.